Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib With or Without Radioiodine (131I) for Advanced Metastatic Differentiated Thyroid Cancer
ChiCTR2200055122Phase 4Recruiting
- Sponsor
- Second Hospital of Shandong University
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of anlotinib in well-differentiated thyroid cancer (WDTC) (2 arms), sponsored by Second Hospital of Shandong University. Primary endpoint: Objective response rate. Started Jan 2022; status: recruiting.
02
Drugs
anlotinib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on ChiCTR2200055122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055122.